Jun Feng

788 total citations
17 papers, 450 citations indexed

About

Jun Feng is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Jun Feng has authored 17 papers receiving a total of 450 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 5 papers in Cancer Research and 4 papers in Oncology. Recurrent topics in Jun Feng's work include Circular RNAs in diseases (5 papers), MicroRNA in disease regulation (4 papers) and Peptidase Inhibition and Analysis (3 papers). Jun Feng is often cited by papers focused on Circular RNAs in diseases (5 papers), MicroRNA in disease regulation (4 papers) and Peptidase Inhibition and Analysis (3 papers). Jun Feng collaborates with scholars based in China, United States and Netherlands. Jun Feng's co-authors include Xing Zhao, Changchun Shao, Jianzhen Xu, Qian Ying, Fan Zhang, Hongyan Dong, Xiaojia Wang, Wen-Jia Chen, Junqing Chen and Xiaolong Wei and has published in prestigious journals such as Blood, PLoS ONE and Applied and Environmental Microbiology.

In The Last Decade

Jun Feng

17 papers receiving 444 citations

Peers

Jun Feng

ONCOL

EDM

Mahmoud Mohamed Mokhtar Egypt

Tânia Capelôa Belgium

Jefferson P. Hemerly Brazil

Aimin Zang China

Zhou‐Tong Dai China

Jiansong Wang China

Tao Ji China

S Shack United States

Xinxin Liu China

Mahmoud Mohamed Mokhtar Egypt

Jun Feng

211 ×0.6

201 ×0.8

41 ×0.6

ONCOL

32 ×0.9

10 ×0.3

EDM

Citations per year, relative to Jun Feng Jun Feng (= 1×) peers Mahmoud Mohamed Mokhtar

Countries citing papers authored by Jun Feng

Since Specialization

Citations

This map shows the geographic impact of Jun Feng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jun Feng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jun Feng more than expected).

Fields of papers citing papers by Jun Feng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jun Feng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jun Feng. The network helps show where Jun Feng may publish in the future.

Co-authorship network of co-authors of Jun Feng

This figure shows the co-authorship network connecting the top 25 collaborators of Jun Feng. A scholar is included among the top collaborators of Jun Feng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jun Feng. Jun Feng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Wang, Weimin, Gang Chen, Ting Wu, et al.. (2023). Discovery of SHR5428 as a selective and noncovalent inhibitor of CDK7. Bioorganic & Medicinal Chemistry Letters. 93. 129429–129429. 3 indexed citations

Feng, Jun, et al.. (2023). The Efficacy and Safety of Patiromer for Heart Failure Patients: A Systematic Review and Meta-Analysis. Cardiovascular Drugs and Therapy. 38(6). 1245–1257. 2 indexed citations

Li, Long, et al.. (2023). Circ-SUZ12 Protects Cardiomyocytes from Hypoxia-Induced Dysfunction Through Upregulating SUZ12 Expression to Activate Wnt/β-catenin Signaling Pathway. International Heart Journal. 64(6). 1113–1124. 5 indexed citations

Li, Chao, et al.. (2022). Circular RNA hsa_circ_0000848 Regulates Cardiomyocyte Proliferation and Apoptosis Under Hypoxia via Recruiting ELAVL1 and Stabilizing SMAD7 mRNA. The Anatolian Journal of Cardiology. 26(3). 189–197. 7 indexed citations

Li, Xin, Yang Chen, Bin Wang, et al.. (2022). Discovery of SHR5133, a Highly Potent and Novel HBV Capsid Assembly Modulator. ACS Medicinal Chemistry Letters. 13(3). 507–512. 4 indexed citations

Gao, Yajuan, Kaini Shen, Jun Feng, et al.. (2022). Efficacy and Safety of Daratumumab Plus Bortezomib and Dexamethasone in Newly Diagnosed Patients with Mayo 2004 Stage 3 Light-Chain Amyloidosis: A Prospective Phase 2 Study. Blood. 140(Supplement 1). 4391–4392. 4 indexed citations

Gao, Si, et al.. (2021). Copy number alterations identify a smoking-associated expression signature predictive of poor outcome in head and neck squamous cell carcinoma. Cancer Genetics. 256-257. 136–148. 1 indexed citations

Cai, Yujie, Xing Zhao, Fan Zhang, et al.. (2021). circ-NOL10 regulated by MTDH/CASC3 inhibits breast cancer progression and metastasis via multiple miRNAs and PDCD4. Molecular Therapy — Nucleic Acids. 26. 773–786. 16 indexed citations

Yu, Zhuo, Jun Feng, Yanan Jiang, et al.. (2020). Emodin succinyl ester inhibits malignant proliferation and migration of hepatocellular carcinoma by suppressing the interaction of AR and EZH2. Biomedicine & Pharmacotherapy. 128. 110244–110244. 19 indexed citations

10.

Xu, Jianzhen, Changchun Shao, Xiaojia Wang, et al.. (2019). circTADA2As suppress breast cancer progression and metastasis via targeting miR-203a-3p/SOCS3 axis. Cell Death and Disease. 10(3). 175–175. 205 indexed citations

11.

Song, Haibin, Zhuo Yu, Xuehua Sun, et al.. (2018). Androgen receptor drives hepatocellular carcinogenesis by activating enhancer of zeste homolog 2-mediated Wnt/β-catenin signaling. EBioMedicine. 35. 155–166. 40 indexed citations

12.

Peng, Jie, et al.. (2018). Long non-coding RNA BCYRN1 promotes the proliferation and metastasis of cervical cancer via targeting microRNA-138 inï¿½vitro and inï¿½vivo. Oncology Letters. 15(4). 5809–5818. 30 indexed citations

13.

Cheruvallath, Zacharia S., Christopher M. McBride, Jun Feng, et al.. (2016). Discovery of potent, reversible MetAP2 inhibitors via fragment based drug discovery and structure based drug design—Part 1. Bioorganic & Medicinal Chemistry Letters. 26(12). 2774–2778. 12 indexed citations

14.

Greig, Michael J., et al.. (2015). Effects of Activating Mutations on EGFR Cellular Protein Turnover and Amino Acid Recycling Determined Using SILAC Mass Spectrometry. International Journal of Cell Biology. 2015. 1–8. 20 indexed citations

15.

Feng, Jun, Jun Wu, Jie Gao, et al.. (2014). Biosynthesis of the β-Methylarginine Residue of Peptidyl Nucleoside Arginomycin in Streptomyces arginensis NRRL 15941. Applied and Environmental Microbiology. 80(16). 5021–5027. 15 indexed citations

16.

Feng, Jun, Jun Wu, Nan Dai, et al.. (2013). Discovery and Characterization of BlsE, a Radical S-Adenosyl-L-methionine Decarboxylase Involved in the Blasticidin S Biosynthetic Pathway. PLoS ONE. 8(7). e68545–e68545. 17 indexed citations

17.

Wallace, Michael B., Jun Feng, Zhiyuan Zhang, et al.. (2008). Structure-based design and synthesis of benzimidazole derivatives as dipeptidyl peptidase IV inhibitors. Bioorganic & Medicinal Chemistry Letters. 18(7). 2362–2367. 50 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact